The story of the blue pill offers a complex case study for stakeholders eyeing pharma. While early sales were astounding, present patent lapse and the emergence of generic versions have severely affected earnings. https://zoeejsx526321.dreamyblogs.com/41335941/the-blue-pill-and-pharma-a-dangerous-investment